DK1151102T3 - Glycosylerede leptinpræparater og relaterede fremgangsmåder - Google Patents

Glycosylerede leptinpræparater og relaterede fremgangsmåder

Info

Publication number
DK1151102T3
DK1151102T3 DK00911784T DK00911784T DK1151102T3 DK 1151102 T3 DK1151102 T3 DK 1151102T3 DK 00911784 T DK00911784 T DK 00911784T DK 00911784 T DK00911784 T DK 00911784T DK 1151102 T3 DK1151102 T3 DK 1151102T3
Authority
DK
Denmark
Prior art keywords
proteins
glycosylated
glycosylated leptin
leptin
methods
Prior art date
Application number
DK00911784T
Other languages
Danish (da)
English (en)
Inventor
Steven G Elliott
Frances H Martin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1151102T3 publication Critical patent/DK1151102T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DK00911784T 1999-02-12 2000-02-11 Glycosylerede leptinpræparater og relaterede fremgangsmåder DK1151102T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24967599A 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
DK1151102T3 true DK1151102T3 (da) 2006-05-29

Family

ID=22944511

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00911784T DK1151102T3 (da) 1999-02-12 2000-02-11 Glycosylerede leptinpræparater og relaterede fremgangsmåder

Country Status (11)

Country Link
EP (1) EP1151102B1 (enExample)
JP (1) JP4841037B2 (enExample)
AT (1) ATE323766T1 (enExample)
AU (1) AU781460B2 (enExample)
CA (1) CA2359840C (enExample)
CY (1) CY1107470T1 (enExample)
DE (1) DE60027409T2 (enExample)
DK (1) DK1151102T3 (enExample)
ES (1) ES2257287T3 (enExample)
PT (1) PT1151102E (enExample)
WO (1) WO2000047741A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
WO2003020303A1 (en) * 2001-08-29 2003-03-13 The University Of Buckingham Use of leptin for infant with low birth weight for prevention of obesity
PL214862B1 (pl) * 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
WO2004064750A2 (en) 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
ATE448312T1 (de) 2003-09-26 2009-11-15 Merck Serono Sa Leitsequenzen zur verwendung bei der produktion von proteinen
EP3061461A1 (en) * 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2008067599A1 (en) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Isolated leptin and adiponectin molecules and chimeric molecules thereof
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
JP2009126856A (ja) * 2007-11-28 2009-06-11 Fancl Corp 血中中性脂肪上昇抑制剤
WO2009143380A2 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
AU2009313562B2 (en) 2008-11-04 2012-11-15 Neurotez, Inc. Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
EP2849567B1 (en) 2012-05-17 2022-03-23 Extend Biosciences, Inc. Carriers for improved drug delivery
RU2650646C2 (ru) 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
DK3074033T3 (en) 2013-11-26 2019-02-11 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2018009921A1 (en) * 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion protein comprising leptin and methods for producing and using the same
MX2019002818A (es) 2016-09-12 2019-08-29 Aegerion Pharmaceuticals Inc Metodos para detectar anticuerpos neutralizantes anti-leptina.
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
ZA946122B (en) * 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU4766596A (en) * 1995-01-31 1996-08-21 Eli Lilly And Company Ob gene product antibodies
ATE259243T1 (de) * 1995-11-22 2004-02-15 Amgen Inc Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
JPH09176198A (ja) * 1995-12-28 1997-07-08 Kikkoman Corp 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ
US5831017A (en) * 1996-01-25 1998-11-03 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
WO1998007446A1 (en) * 1996-08-23 1998-02-26 Eli Lilly And Company Protein formulations
WO1999023115A1 (en) * 1997-10-31 1999-05-14 Eli Lilly And Company Glycosylated obesity protein analogs
AU5347099A (en) * 1998-08-10 2000-03-06 Amgen, Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Also Published As

Publication number Publication date
AU3362300A (en) 2000-08-29
ATE323766T1 (de) 2006-05-15
CA2359840A1 (en) 2000-08-17
AU781460B2 (en) 2005-05-26
EP1151102A1 (en) 2001-11-07
CY1107470T1 (el) 2012-12-19
ES2257287T3 (es) 2006-08-01
DE60027409D1 (de) 2006-05-24
PT1151102E (pt) 2006-07-31
WO2000047741A1 (en) 2000-08-17
JP2002536018A (ja) 2002-10-29
JP4841037B2 (ja) 2011-12-21
CA2359840C (en) 2012-10-23
DE60027409T2 (de) 2007-04-12
EP1151102B1 (en) 2006-04-19

Similar Documents

Publication Publication Date Title
DK1151102T3 (da) Glycosylerede leptinpræparater og relaterede fremgangsmåder
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
EP2325205A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2003059934A3 (en) Albumin fusion proteins
BR0007840A (pt) Proteìnas de fusão her-2/neu
YU48703A (sh) Novi interferonu beta-slični molekuli
ATE112801T1 (de) Menschliche lactoferrin-cdna-sequenz.
EP0797999A3 (en) Formulations of obesity protein
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
IL81221A0 (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
HUP0100267A2 (hu) Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények
DE60118359D1 (de) Humanische pellino-polypeptide
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
CA2002833A1 (en) Interferon-gamma binding proteins
AUPM772494A0 (en) Improvements in production of proteins in host cells
BR0211991A (pt) HormÈnio do crescimento humano modificado
WO2002007514A3 (en) Glycosylated vegf-b and method for increasing the amount of soluble vegf-b
WO1998021231A3 (en) Streptococcus uberis lactoferrin-binding protein